Surveillance of the susceptibility of ocular bacterial pathogens to the fluoroquinolone gatifloxacin and other antimicrobials in Europe during 2001/2002

The Journal of Infection
Ian MorrisseyMarion Robbins

Abstract

To determine the identity of European ocular bacterial pathogens and their susceptibility to topical antimicrobial agents. Bacterial isolates derived from clinically significant ocular infections were collected from 10 European centres. Bacteria were re-identified and susceptibility to gatifloxacin, ciprofloxacin, ofloxacin, fusidic acid, gentamicin and chloramphenicol was determined using the NCCLS agar incorporation method at a central testing laboratory. Five hundred and thirty-two isolates were submitted for analysis. The most common pathogen was methicillin-susceptible Staphylococcus aureus, followed by Haemophilus influenzae and Streptococcus pneumoniae. Gatifloxacin was the most potent antimicrobial agent tested for isolates from each European country as measured by pure MIC or percentage resistance (using 95% confidence intervals). Only methicillin-resistant S. aureus was in any way refractory to the action of gatifloxacin and other fluoroquinolones. Fluoroquinolones offer broad-spectrum coverage for the treatment of ocular pathogens. Gatifloxacin ophthalmic solution should be a significant improvement on currently available fluoroquinolones mainly due to enhanced activity against streptococci and coagulase-negative sta...Continue Reading

Citations

Jun 24, 2006·Ophthalmic & Physiological Optics : the Journal of the British College of Ophthalmic Opticians (Optometrists)·Michael J Doughty, Gordon N Dutton
Feb 1, 2013·Journal of Ophthalmology·Mary E Marquart, Richard J O'Callaghan
Sep 26, 2013·BioMed Research International·Jayaraman KaliamurthyPhilip A Thomas
Sep 23, 2014·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Warren HellerHarold Jensen
Jan 8, 2014·Expert Review of Anti-infective Therapy·Rok ČivljakNicola Petrosillo
Mar 28, 2009·Current Medical Research and Opinion·Michael E TepedinoTimothy L Comstock
Feb 12, 2014·Canadian Journal of Ophthalmology. Journal Canadien D'ophtalmologie·Stephen J DorrepaalSanjay Sharma
Aug 10, 2010·Journal of Cataract and Refractive Surgery·Marguerite McDonald, Joseph M Blondeau
Feb 18, 2011·Pediatric Annals·Robert S Gold
May 31, 2007·Clinical & Experimental Optometry : Journal of the Australian Optometrical Association·Lindsay Brown
Nov 19, 2010·Clinical & Experimental Optometry : Journal of the Australian Optometrical Association·Mark D P Willcox
Feb 15, 2015·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·C ChiquetA Carricajo
Jan 1, 2011·Ophthalmology and Eye Diseases·D Bremond-GignacS Milazzo
Sep 15, 2010·Optometry and Vision Science : Official Publication of the American Academy of Optometry·Paul KarpeckiTimothy L Comstock
Jan 26, 2007·Cornea·Adália Dias Dourado OliveiraWaldemar Francisco
Sep 8, 2010·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·Z WuH Chen
Oct 25, 2006·International Ophthalmology Clinics·Randall Olson
Dec 27, 2019·European Journal of Ophthalmology·Giuseppe GrandiCristina Costa
Aug 11, 2012·Eye & Contact Lens·Namrata SharmaRasik B Vajpayee
Nov 13, 2012·Optometry and Vision Science : Official Publication of the American Academy of Optometry·Tushar AgarwalJeewan S Titiyal
Feb 8, 2021·Experimental Eye Research·Konduri RanjithSisinthy Shivaji
May 3, 2021·Antimicrobial Resistance and Infection Control·Bahareh HajikhaniMasoud Dadashi
Aug 24, 2011·Indian Journal of Medical Microbiology·S Sharma

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.